Elad Sharon

Elad Sharon: Contribution of effect is an under appreciated and essential part of drug development

Elad Sharon, Clinical and Translational Director of Dana-Farber Cancer Institute, shared a post by FDA Oncology on X:

“Absolutely, the right message to send… Contribution of effect is an under appreciated and essential part of drug development.

I don’t even think the perioperative period is the most essential place to start… but you gotta start somewhere.”

Quoting FDA Oncology’s post:

“Oncologic Drugs Advisory Committee votes 11 to 0 in favor of FDA requiring that new trial design proposals for perioperative regimens for resectable NSCLC include adequate within trial assessment of contribution of treatment phase.”

Elad Sharon

Link to video.
Source: Elad Sharon/X and FDA Oncology/X

 

cancer Dana-Farber Cancer Institute drug development Elad Sharon FDA FDA Oncology NSCLC ODAC OncoDaily Oncologic Drugs Advisory Committee Oncology